Eli Lilly, Novo Nordisk race to lock in India obesity drug market We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Drugmaker Cipla on Wednesday said it has launched a medication for managing obesity and type-2 diabetes mellitus. The company has launched Yurpeak (tirzepatide), a one-weekly injectable therapy for obesity and type-2 diabetes mellitus, two of the country’s most pressing health challenges, the Mumbai-based drugmaker said in a regulatory filing. The company has the rights to…
From Launch to Leadership: Mounjaro Crosses Rs 333 Crore, Becomes India’s Top-Selling Drug We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
US pharma major Eli Lilly has tied up with Indian drug major Cipla to market and distribute a second brand of its breakthrough weight-loss and diabetes drug tirzepatide in India. The drug under the new brand name, Yurpeak, will be priced the same as the existing Mounjaro brand, which was launched in India in mid-March….